NanoMedSyn develops a new addressing process for therapeutics. Its development plan is based on a strong intellectual property of patented synthetic derivatives called AMFA, designed for the targeting of a specific membrane lectin, the cation-independent mannose 6-phosphate receptor (CI-M6PR), the major addressing pathway to lysosomes. These AMFA compounds have the potential to target various proteins or drugs to tissues and cells expressing these receptors in order to facilitate their cellular entrance and finally lysosomal addressing.
NanoMedSyn develops research agreements and sublicensing of AMFA technology with partners on the following applications.
ENZYME REPLACEMENT THERAPY OF LYSOSOMAL STORAGE DISEASES
The main application is the production of new modified recombinant enzymes for the treatment by Enzyme Replacement Therapy of lysosomal storage disorders. Thanks to the results obtained in the preclinical phases, NanoMedSyn was granted by E.M.A. the orphan drug designation for its first compound, recombinant acid alpha-glucosidase conjugated with AMFA, aimed for the treatment of Pompe disease. Moreover, the recent analysis of the specific activity of AMFA on the therapeutic enzyme maturation suggests the wide application of this technology for a part of the 53 lysosomal diseases.
TARGETING CI-M6PR-RICH CANCERS
NanoMedSyn has demonstrated the capacity of AMFA to target therapeutics in cancer cells overexpressing CI-M6PR such as prostate cancers and rhabdomyosarcomas. Preclinical studies are in progress with different AMFA-grafted nanoparticles and drugs.
NanoMedSyn’s development plan is based on a strong intellectual property of patented synthetic derivatives called AMFA.
is the production of new modified recombinant enzymes for the treatment of orphan lysosomal storage disorders.
NanoMedSyn has decided to develop new AMFA-modified therapeutics and AMFA-targeted nanoparticles.